Low-Dose Adefovir Dipivoxil May Induce Fanconi Syndrome: Clinical Characteristics and Long-Term follow-up for Chinese Patients

Abstract

Background

Adefovir dipivoxil (ADV) nephrotoxicity is well known at a dose of 60 mg day^-1 or 120 mg day^-1. However, renal toxicity at a low-dose of 10 mg ADV for HBV-infected patients is not fully described. Our objective was to analyse the clinical features and outcomes of ADV-related Fanconi's syndrome in the Chinese population.

Methods

This was a retrospective study. A total of 35 patients with ADV-related Fanconi's syndrome were studied. Clinical manifestations and biochemical parameters were analysed. 19 patients were from Peking Union Medical College Hospital (PUMCH) included from August 2010 to December 2012. A total of 16 patients were eligible from case reports in the Chinese population retrieved in PUBMED, WANFANG and CNKI database. Bone mineral density and biochemical parameters including serum phosphate, calcium, creatinine, alkaline phosphatase (ALP) were measured before and after ADV cessation and during the follow-up.

Results

All recruited patients had hypophosphataemia, increased urinary phosphate excretion and elevated alkaline phosphatase. Serum phosphate levels rapidly increased especially within the 4 weeks after ADV cessation. Serum creatinine remained high or at the upper limit of normal range even after ADV cessation for 1 year. ALP increased in the first three months of ADV cessation and decreased at the 24th week. Bone mineral density was significantly improved after 6 months cessation of ADV.

Conclusions

ADV can be nephrotoxic at prolonged low doses of 10 mg. For those who take ADV long term, regular monitoring of serum phosphate, creatinine levels and urine routine tests are required.

References

Chinese Society of Hepatology and Chinese Society of Infectious Diseases.

Chinese Medical Association: The guideline of prevention and treatment for chronic hepatitis B (2010 version).

Zhonghua Gan Zang Bing Za Zhi 2011; 19: 13–24. Chinese.

Fontana

R.J.

Side effects of long-term oral antiviral therapy for hepatitis B.

Hepatology 2009; 49 Suppl 5: S185–S195.

Kahn

, Lagakos

, Wulfsohn

Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial.

JAMA 1999; 282: 2305–2312.

Law

S.T.

, Li

K.K.

, Ho

Y Y.

Nephrotoxicity, including acquired Fanconi's syndrome, caused by adefovir dipivoxil – is there a safe dose?

J Clin Pharm Ther 2012; 37: 128–131.

Kim du

, Sung

D.H.

, Min

Y.K.

Hypophosphatemic osteomalacia induced by low-dose adefovir therapy: focus on manifestations in the skeletal system and literature review.

J Bone Miner Metab 2013; 31: 240–246.

Yan

X.B.

, Xu

, Zhou

P.P.

A case with poly-bone pain, decrease of bone density and increase of serum creatinine related to adefovir dipivoxil treatment in a chronic hepatitis B patient.

Zhonghua Gan Zang Bing Za Zhi 2011; 19: 383–384. Chinese.

Zhang

R.M.

, Zhang

L.X.

, Liu

S.H.

Four cases of adefovir dipivoxil induced increased urea nitrogen.

Zhongguo Yi Yuan Yao Xue Za Zhi 2008; 28: 2152–2153. Chinese.

Wang

, Ren

, Ye

S.D.

A case of adefovir dipivoxil induced Fanconi's syndrome.

Zhonghua Nei Ke Za Zhi 2011; 50: 971–972. Chinese.

Wang

Y.Y.

, Cheng

, Wang

G.Q.

A case of adefovir dipivoxil induced Fanconi's syndrome.

Zhonghua Shen Zang Bing Za Zhi 2012; 28: 578–579. Chinese.

10.

P.J.

, Shao

M.W.

, Huang

A case of adefovir dipivoxil induced Fanconi's syndrome.

Zhonghua Shen Zang Bing Za Zhi 2012; 28: 665. Chinese.

11.

Zhao

H.Q.

, Han

W.M.

Two cases of adefovir dipivoxil induced renal impairment.

Yao Wu Bu Liang Fan Ying Za Zhi 2010; 12: 213–214. Chinese.

12.

Chen

X.Z.

, Li

Two cases of adefovir dipivoxil induced tubulopathy.

Yao Wu Bu Liang Fan Ying Za Zhi 2011; 13: 51–52. Chinese.

13.

, Ba

J.M.

, Gu

W.J.

Renal tubular acidosis and secondary hypophosphatemia osteomalacia caused by adefovir dipivoxil:3 cases report.

Zhongguo Gu Zhi Shu Song Za Zhi 2012; 18: 1058–1061. Chinese.

14.

Guo

, He

D.C.

A case of hypophosphatemic osteomalacia with Fanconi's syndrome.

Shan Xi Yi Ke Da Xue Xue Bao 2012; 43: 717–718. Chinese.

15.

Wang

, Mu

H.J.

, Qin

F.B.

Adefovir dipivoxil induced Fanconi's syndrome in a patient with chronic hepatitis B.

Zhonghua Lin Chuang Yi Shi Za Zhi 2012; 6: 4150–4152. Chinese.

16.

, Dong

G.F.

, Zhang

Adefovir dipivoxil-induced Fanconi's syndrome and hypophosphatemic osteomalacia associated with muscular weakness in a patient with chronic hepatitis B.

Nan Fang Yi Ke Da Xue Xue Bao 2011; 31: 1956–1957. Chinese.

17.

Bai

Adefovir dipivoxil-induced Fanconi's syndrome in a patient with chronic hepatitis B.

Gang Zang 2011; 16: 437. Chinese.

18.

Zhang

, Huang

, Wang

L.J.

Adefovir dipivoxil-related nephropathy misdiagnosed as primary osteoporosis: a case report.

Zhonghua Gu Zhi Shu Song He Gu Kuang Yan Ji Bing Za Zhi 2012; 5: 316–319. Chinese.

19.

Sun

X.F.

, Zhang

H.B.

, Li

X.P.

A case of adefovir dipivoxil induced hypophosphataemic osteomalacia and literature review.

Zhonghua Nei Ke Za Zhi 2011; 50: 754–757. Chinese.

20.

Walton

R.J.

, Bijvoet

O.L.

A simple slide-rule method for the assessment of renal tubular reaborption of phosphate in man.

Clin Chim Acta 1977; 81: 273–276.

21.

Shimohata

, Sakai

, Ogawa

Osteomalacia due to Fanconi's syndrome and renal failure caused by long-term low-dose adefovir dipivoxil.

Clin Exp Nephrol 2013; 17: 147–148.

22.

Girgis

C.M.

, Wong

, Ngu

M.C.

Hypophosphataemic osteomalacia in patients on adefovir dipivoxil.

J Clin Gastroenterol 2011; 45: 468–473.

23.

Lee

H.J.

, Choi

J.W.

, Kim

T.N.

A case of severe hypophosphatemia related to adefovir dipivoxil treatment in a patient with liver cirrhosis related to hepatitis B virus.

Korean J Hepatol 2008; 14: 381–386.

24.

Tamori

, Enomoto

, Kobayashi

Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus.

J Viral Hepat 2010; 17: 123–129.

25.

Tanaka

, Setoguchi

, Ishidou

Pathological femoral fractures due to osteomalacia associated with adefovir dipivoxil treatment for hepatitis B: a case report.

Diagn Pathol 2012; 7: 108.

26.

Minemura

, Tokimitsu

, Tajiri

Development of osteomalacia in a post-liver transplant patient receiving adefovir dipivoxil.

World J Hepatol 2010; 2: 442–446.

27.

Jung

Y.K.

, Yeon

J.E.

, Choi

J.H.

Fanconi's syndrome associated with prolonged adefovir dipivoxil therapy in a hepatitis B virus patient.

Gut Liver 2010; 4: 389–393.

28.

Wong

, Girgis

C.M.

, Ngu

M.C.

Hypophosphatemic osteomalacia after low-dose adefovir dipivoxil therapy for hepatitis B.

J Clin Endocrinol Metab 2010; 95: 479–480.

29.

Shimizu

, Hiraoka

, Yamago

Hypophosphatemia in patients with hepatitis B virus infection undergoing long-term adefovir dipivoxil therapy.

Hepatol Res 2014; 44: 1081–1087.

30.

Marcellin

, Chang

T.T.

, Lim

S.G.

Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

Hepatology 2008; 48: 750–758.

31.

Tanji

, Tanji

, Kambham

, Markowitz

G.S.

, Bell

, D'agati

V.D.

Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion.

Hum Pathol 2001; 32: 734–740.

32.

Izzedine

, Launay-Vacher

, Deray

Antiviral drug induced nephrotoxicity.

Am J Kidney Dis 2005; 45: 804–817.

33.

Viganò

, Lampertico

, Colombo

Drug safety evaluation of adefovir in HBV infection.

Expert Opin Drug Saf 2011; 10: 809–818.

34.

Viganò

, Lampertico

, Dongiovanni

A drug transporter gene polymorphism predicts renal tubular toxicity in patients with chronic hepatitis B on long-term adefovir and lamivudine combination.

J Hepatol 2010; 52 Suppl 1: S7.